TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38926753

Group type: EXPERIMENTAL
Intervention: Patients with CAD (females)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Patients with CAD (males)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Patients with low LDL-c and CAD (males)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Patients without CAD (females)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Patients without CAD (males)
Number of subjects: 177
Study: 38926810

Group type: EXPERIMENTAL
Intervention: Tailored Best Practices (TBP)
Number of subjects: 415

Group type: COMPARATOR
Intervention: General Best Practices (GBP)
Number of subjects: 415
Study: 38926901

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training, 3 times per week, duration ranging from 30 to 45 minutes over 4 months.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 28
Study: 38926908

Group type: EXPERIMENTAL
Intervention: Patients who received a waiver (pW)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Patients who did not receive a waiver (pNW)
Number of subjects: 1019
Study: 38927068

Group type: EXPERIMENTAL
Intervention: Ketone ester beverage delivering β-hydroxybutyrate (KEβHB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38927884

Group type: EXPERIMENTAL
Intervention: NanoKnife System (IRE)
Number of subjects: 121
Study: 38927991

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nivolumab+Ipilimumab boosts
Number of subjects: 207
Study: 38929215

Group type: EXPERIMENTAL
Intervention: Personalized Mediterranean diet (MD) plans delivered via a clinical decision support system (CDSS) every 15 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: General nutritional advice (Control)
Number of subjects: 40
Study: 38930117

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38931260

Group type: EXPERIMENTAL
Intervention: Standard dose of DMB (150 mg DMB/tablet)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High dose of DMB (300 mg DMB/tablet)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (300 mg freeze-dried strawberry)
Number of subjects: 31
Study: 38931864

Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer vaccine candidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purified products from 1 L scale
Number of subjects: 0
Study: 38932417

Group type: EXPERIMENTAL
Intervention: L2-based target antigen (LBTA) vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38932575

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14543
Study: 38932583

Group type: EXPERIMENTAL
Intervention: Tafamidis (80 mg meglumine or 61 mg free acid)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 38932589

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 1000

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 1000
Study: 38932723

Group type: EXPERIMENTAL
Intervention: Padsevonil
Number of subjects: 0
Study: 38933370

Group type: EXPERIMENTAL
Intervention: Injury Prevention Exercise Programmes (IPEPs)
Number of subjects: 514
Study: 38933603

Group type: EXPERIMENTAL
Intervention: Patients with at least a single documented adverse event (AE)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Patients with multiple adverse events (>1 AE)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Overall documented adverse events (AEs)
Number of subjects: 1490
Study: 38934093

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + Ipilimumab (I) and/or Nivolumab (N)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) + Nivolumab (N) and Brentuximab vedotin (BV) + Ipilimumab (I) + Nivolumab (N)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Brentuximab vedotin (BV) + Ipilimumab (I)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Baseline or after one treatment cycle
Number of subjects: 54
Study: 38934112

Group type: EXPERIMENTAL
Intervention: LDV-based cfPWV measurement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Applanation tonometry (Sphygmocor)
Number of subjects: 100
Study: 38934111

Group type: EXPERIMENTAL
Intervention: Multifaceted clinic-based intervention
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1045
Study: 38934147

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200/50-mg
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 10-mg
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (any dose)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo switched to Ritlecitinib
Number of subjects: 718
Study: 38934229

Group type: EXPERIMENTAL
Intervention: Maternal CYP2B6 genotype (fast, intermediate, slow)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Newborn CYP2B6 genotype (fast, intermediate, slow)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Maternal and newborn efavirenz concentration correlation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Newborn plasma-to-maternal plasma ratio
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cord-to-maternal plasma ratio
Number of subjects: 112
Study: 38934231

Group type: EXPERIMENTAL
Intervention: CaHA-CMC(+) injections
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control/delayed treatment group
Number of subjects: 175
Study: 38934517

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (75 min/session, 3 times a week for 16 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 38934602

Group type: EXPERIMENTAL
Intervention: Continuous unfractionated heparin (UFH) infusion at 10 to 15 units/kg/h for infants with CRT and 2 to 3 units/kg/h without CRT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuous unfractionated heparin (UFH) infusion
Number of subjects: 35
Study: 38934714

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 27
Study: 38934799

Group type: EXPERIMENTAL
Intervention: Medical therapy alone
Number of subjects: 165

Group type: COMPARATOR
Intervention: Bypass surgical group
Number of subjects: 165
Study: 38934845

Group type: EXPERIMENTAL
Intervention: mRNA-1010 (6.25 µg to 200 µg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mRNA-1010 (25 µg to 200 µg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mRNA-1010 (6.25 µg to 25 µg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mRNA-1010 (50 µg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: mRNA-1010
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Afluria
Number of subjects: 100
Study: 38934914

Group type: EXPERIMENTAL
Intervention: Multisession attentional bias modification (ABM) training, details on dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38934966

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) added to intravenous furosemide regimen
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo added to intravenous furosemide regimen
Number of subjects: 230
Study: 38934964

Group type: EXPERIMENTAL
Intervention: Corvia Atrial Shunt
Number of subjects: 621

Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 621
Study: 38934967

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study: 38934968

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly subcutaneous injections
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 38935053

Group type: EXPERIMENTAL
Intervention: Nurse-led brief behavioral treatment for insomnia (BBTI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sleep hygiene group
Number of subjects: 42
Study: 38935059

Group type: EXPERIMENTAL
Intervention: Fentanyl-test (1 mcg/kg fentanyl administration)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fentanyl-test (FRR > 53%)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nadir pulse oxygen saturation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fentanyl-test (FRR)
Number of subjects: 240
Study: 38935085

Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation (EX)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 71
Study: 38935125

Group type: EXPERIMENTAL
Intervention: Primary tumor resection and systemic treatment (PTR+SYST)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Systemic treatment only (SYST)
Number of subjects: 480
Study: 38935202

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 1045
Study: 38935213

Group type: EXPERIMENTAL
Intervention: Overdose education and naloxone distribution (OEND) implementation in jails
Number of subjects: 0
Study: 38935259

Group type: EXPERIMENTAL
Intervention: Multi-species probiotic (Lactobacillus rhamnosus and Bifidobacterium lactis)
Number of subjects: 33
Study: 38935373

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 483

Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiotherapy (3D-CRT)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Heart V40 (<20%)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Heart V40 (≥20%)
Number of subjects: 483

Group type: COMPARATOR
Intervention: IMRT and 3D-CRT
Number of subjects: 483
Study: 38935379

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: App group
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: App plus feedback group
Number of subjects: 304
Study: 38935400

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation with C-loop IOL
Number of subjects: 186

Group type: COMPARATOR
Intervention: C-loop IOL only (control group)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation with C-loop IOL (in eyes with AL ≥30 mm)
Number of subjects: 186

Group type: COMPARATOR
Intervention: C-loop IOL only (control group, in eyes with AL ≥30 mm)
Number of subjects: 186
Study: 38935428

Group type: EXPERIMENTAL
Intervention: Telehealth Serious Illness Care Program (SICP)
Number of subjects: 20
Study: 38935496

Group type: EXPERIMENTAL
Intervention: High-Speed Resistance Training (HSRT) for 16 weeks, 3 sessions per week, 60-70 minutes per session, 5-6 exercises, 2-3 sets, 6-10 reps/exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (CG) did not perform any exercise training program
Number of subjects: 79
Study: 38935839

Group type: EXPERIMENTAL
Intervention: HLA-mismatched allogeneic adoptive immune therapy (AAIT) in combination with ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ART-only regimen
Number of subjects: 0
Study: 38935923

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab emtansine (T-DM1) for 1 year
Number of subjects: 187

Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab (TH)
Number of subjects: 187
Study: 38936378

Group type: EXPERIMENTAL
Intervention: VAC/VI with temsirolimus
Number of subjects: 297

Group type: COMPARATOR
Intervention: VAC/VI alone
Number of subjects: 297
Study: 38936379

Group type: EXPERIMENTAL
Intervention: RIST (irinotecan-temozolomide and dasatinib-rapamycin)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (irinotecan-temozolomide)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: RIST (in patients with amplified MYCN)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (in patients with amplified MYCN)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: RIST (in patients without amplified MYCN)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (in patients without amplified MYCN)
Number of subjects: 129
Study: 38936466

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 50/25 µg once daily
Number of subjects: 902

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 50 µg once daily
Number of subjects: 902
Study: 38936469

Group type: EXPERIMENTAL
Intervention: Early venting within 24 hours of ECMO insertion
Number of subjects: 217

Group type: COMPARATOR
Intervention: No or delayed unloading (venting)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Patients not experiencing the primary outcome within 6 months
Number of subjects: 217
Study: 38936548

Group type: EXPERIMENTAL
Intervention: Term SGA
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Term AGA
Number of subjects: 1441
Study: 38936550

Group type: EXPERIMENTAL
Intervention: Juice introduction <6 months
Number of subjects: 524

Group type: COMPARATOR
Intervention: Juice introduction 6 to <12 months
Number of subjects: 524

Group type: COMPARATOR
Intervention: Juice introduction ≥12 months
Number of subjects: 524
Study: 38936652

Group type: EXPERIMENTAL
Intervention: Targeted mild hypercapnia
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normocapnia
Number of subjects: 125
Study: 38936755

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine 0.5 mg daily
Number of subjects: 7062

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 7062

Group type: COMPARATOR
Intervention: Placebo for colchicine
Number of subjects: 7062

Group type: COMPARATOR
Intervention: Placebo for spironolactone
Number of subjects: 7062
Study: 38937182

Group type: EXPERIMENTAL
Intervention: Four-dose test group (2-1-1 regimen)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Four-dose control group
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Five-dose control group
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Four-dose test group
Number of subjects: 1800
Study: 38937298

Group type: EXPERIMENTAL
Intervention: Fulvestrant alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fulvestrant in combination with taselisib (PI3K inhibitor)
Number of subjects: 0
Study: 38937310

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) integration, monthly meetings with a palliative care team for 12 months
Number of subjects: 20
Study: 38937331

Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate (CH) content
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Increased protein content
Number of subjects: 71

Group type: COMPARATOR
Intervention: Physical activity (PA)
Number of subjects: 71
Study: 38937404

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg initial doses at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks or CZP 400 mg every 2 weeks maintenance dosing.
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 399
Study: 38937412

Group type: EXPERIMENTAL
Intervention: Resectability status (borderline versus resectable)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Resectability status (locally advanced versus resectable)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Tumor location (head versus body/tail)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Vascular resection
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Perineural invasion
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Number of positive lymph nodes
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Resection margin status (R1 < 1 mm versus R0 ≥ 1 mm)
Number of subjects: 1693
Study: 38937446

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 41
Study: 38937667

Group type: EXPERIMENTAL
Intervention: Home-based gait, balance, and resistance exercise intervention
Number of subjects: 0
Study: 38937696

Group type: EXPERIMENTAL
Intervention: Occupational burnout assessment using Maslach Burnout Inventory (MBI-ES)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Socio-demographic, lifestyle, and work-related factors
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Teaching special needs students
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Low physical activity and alcohol intake
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Younger age, being married, language of teaching, having a disability, sub-optimal physical fitness, poor sleep quality, and ever smoking
Number of subjects: 218
Study: 38937769

Group type: EXPERIMENTAL
Intervention: Automated intervention
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Blended intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 264
Study: 38937776

Group type: EXPERIMENTAL
Intervention: VR-CET + CBT
Number of subjects: 156

Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 156
Study: 38937792

Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical treatment of surgeon's choice
Number of subjects: 40
Study: 38937798

Group type: EXPERIMENTAL
Intervention: Personalized Citizen Assistance for Social Participation (APIC); weekly 3-h personalized stimulation sessions given by a trained volunteer over a 12-month period
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adapted intervention for remote delivery via telephone or videoconferencing due to COVID-19 restrictions
Number of subjects: 14
Study: 38937803

Group type: EXPERIMENTAL
Intervention: Haploidentical CD34+ enriched and CD45RA-depleted hematopoietic progenitor cell grafts followed by NK-cell infusion
Number of subjects: 72
Study: 38937824

Group type: EXPERIMENTAL
Intervention: Virtual reality cue-exposure therapy (VRCET) plus memory-focused cognitive therapy (MFCT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Picture-based cue-exposure therapy (PCET)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VRCET
Number of subjects: 54

Group type: COMPARATOR
Intervention: PCET
Number of subjects: 54
Study: 38937954

Group type: EXPERIMENTAL
Intervention: Multimodal anaesthesia and analgesia with opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (for both pain-sensitive and pain-tolerant groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 38938171

Group type: EXPERIMENTAL
Intervention: Napping on school days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Napping on weekends
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Early wake times
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Long and late naps on school days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Napping duration and timing
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Nocturnal sleep duration
Number of subjects: 153
Study: 38938363

Group type: EXPERIMENTAL
Intervention: AliveCor KardiaMobile 1L ECG
Number of subjects: 14230
Study: 38938387

Group type: EXPERIMENTAL
Intervention: Self-administered SAGE used during PCP visits
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (PCP visits without SAGE)
Number of subjects: 300
Study: 38938412

Group type: EXPERIMENTAL
Intervention: Attention test (Continuous Performance Task)
Number of subjects: 20
Study: 38938519

Group type: EXPERIMENTAL
Intervention: Human milk from GDM+ women
Number of subjects: 53

Group type: COMPARATOR
Intervention: Human milk from GDM- women
Number of subjects: 53
Study: 38938704

Group type: EXPERIMENTAL
Intervention: Standardized use of accepted criteria for PAH diagnosis with pop-up reminders during data entry.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiogram (TTE) assessment.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Right heart catheterization (RHC).
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Structured protocol for screening.
Number of subjects: 217
Study: 38938712

Group type: EXPERIMENTAL
Intervention: K-Clip system
Number of subjects: 39
Study: 38939193

Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 0

Group type: COMPARATOR
Intervention: laTME
Number of subjects: 0
Study: 38939366

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet for 4 weeks
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Starch- and sucrose-reduced diet (SSRD) for 4 weeks
Number of subjects: 155
Study: 38939381

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography with fractional flow reserve
Number of subjects: 50
Study: 38939389

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Vitamin K Antagonist (VKA)
Number of subjects: 1455
Study: 38939428

Group type: EXPERIMENTAL
Intervention: CR intervention (multidisciplinary model of cardiac rehabilitation including guideline-directed management of cardiovascular risk factors, dietary counselling, and supervised exercise for 52 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CR intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 74
Study: 38939456

Group type: EXPERIMENTAL
Intervention: Tafamidis (80 mg or 20 mg)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 38939480

Group type: EXPERIMENTAL
Intervention: Recommended dose edoxaban
Number of subjects: 176
Study: 38939496

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/d)
Number of subjects: 2814

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2814
Study: 38939518

Group type: EXPERIMENTAL
Intervention: anti-PD1 treatment
Number of subjects: 0
Study: 38939580

Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 1019
Study: 38939586

Group type: EXPERIMENTAL
Intervention: ST-segment elevation myocardial infarction (STEMI)
Number of subjects: 87812

Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation ACS (NSTE-ACS)
Number of subjects: 87812
Study: 38939629

Group type: EXPERIMENTAL
Intervention: Organized treatment pathway
Number of subjects: 500

Group type: COMPARATOR
Intervention: Routine-care approach (Control)
Number of subjects: 500
Study: 38939651

Group type: EXPERIMENTAL
Intervention: In-hospital multicomponent exercise program for 3, 4, or 5-7 consecutive days
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: 4-day exercise program
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: 5-7 day exercise program
Number of subjects: 570